Gándara-Cortes Marina, Vázquez-Boquete Ángel, Fernández-Rodríguez Beatriz, Viaño Patricia, Ínsua Dora, Seoane-Seoane Alejandro, Gude Francisco, Gallego Rosalía, Fraga Máximo, Antúnez José R, Curiel Teresa, Pérez-López Eva, García-Caballero Tomás
Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
Department of Pathology, Alvaro Cunqueiro University Hospital, Vigo, Spain.
Virchows Arch. 2018 Feb;472(2):195-203. doi: 10.1007/s00428-017-2194-z. Epub 2017 Aug 20.
Breast cancer is a heterogeneous disease. Surrogate classification of intrinsic subtypes of invasive carcinomas by combined immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 (4-IHC) has increased steadily since the 2011 St Gallen symposium, due to its rapid subtyping of tumors at a reasonable cost. An important step in improving 4-IHC reproducibility and reliability will be to provide reference values from the routine use of standardized 4-IHC followed by image analysis. The aims of the current study were (1) to analyze invasive breast carcinomas using standardized 4-IHC and quantitative image analysis and (2) to compare the results obtained in the classification of biological subtypes using current Ki67 and PR threshold values proposed by different authors to sub-classifying the luminal A-like and the luminal B-like (HER2-negative) subtypes. Five hundred twenty-one tumors were analyzed by standardized immunohistochemistry, with automatic image analysis, and HER2 FISH technique. Positivity for ER was found in 82.7% and for PR in 70.1% of cases. Using the Allred scoring system, hormone receptor results showed a bimodal distribution, particularly for ER. HER2 positivity was found in 15.7% of cases, and the mean Ki67 score was 32.3%. Using the most recently proposed surrogate definitions for the classification of luminal breast cancer subtypes, the percentages of different subtypes that we found were similar to those published with genomic platforms: 40.7% luminal A-like, 32.4% luminal B-like/HER2-negative, 9.8% luminal B-like/HER2-positive, 6.0% HER2-positive, and 11.1% triple negative. Standardized 4-IHC with automatic image analysis constitutes a low-cost method for surrogate definitions of biological subtypes of breast cancer that delivers accurate results in a day.
乳腺癌是一种异质性疾病。自2011年圣加仑研讨会以来,通过联合雌激素受体(ER)、孕激素受体(PR)、HER2和Ki67的免疫组织化学(4-IHC)对浸润性癌的内在亚型进行替代分类稳步增加,这是因为它能以合理的成本快速对肿瘤进行亚型分类。提高4-IHC重现性和可靠性的一个重要步骤是提供标准化4-IHC常规使用并随后进行图像分析的参考值。本研究的目的是:(1)使用标准化4-IHC和定量图像分析来分析浸润性乳腺癌;(2)比较使用不同作者提出的当前Ki67和PR阈值对生物学亚型进行分类的结果与对腔面A型和腔面B型(HER2阴性)亚型进行再分类的结果。通过标准化免疫组织化学、自动图像分析和HER2 FISH技术对521个肿瘤进行了分析。82.7%的病例ER呈阳性,70.1%的病例PR呈阳性。使用奥尔雷德评分系统,激素受体结果显示为双峰分布,尤其是ER。15.7%的病例HER2呈阳性,Ki67平均评分为32.3%。使用最近提出的用于腔面型乳腺癌亚型分类的替代定义,我们发现的不同亚型的百分比与使用基因组平台公布的结果相似:40.7%为腔面A型,32.4%为腔面B型/HER2阴性型,9.8%为腔面B型/HER2阳性型,6.0%为HER2阳性型,11.1%为三阴性型。标准化4-IHC与自动图像分析构成了一种低成本方法,用于乳腺癌生物学亚型的替代定义,并能在一天内提供准确结果